This report introduces the composition and methods of the improved passive immunity. In a manner, it provides an ingredient that includes a specific polychlorinated antibody synergy in the carrier matrix. This description provides a cost-effective and effective ingredient and method for the treatment of diarrhea and intestinal infection, with a wide range of clinical applications, Non differential or complex requirement 1: ingredients with the following characteristics: (a) non neonatal effective quantity with at least one specific can molecule or its fragments,1. Extract and specifically bind antigens from animals, in which specific can molecules are selected from immunoglobulin, antibody, peptide, variable lymphocyte receptor, cell receptor, transfer factor and mixture； (b) A matrix of vectors in which at least two components are from a group of non-human animals, including enzymes, lactate ferrina, transfer agents, non-specific immunoglobulins, cells, leukocytes, supplement components, interference agents and cellulose,At least one specific linker and at least two carrier matrix components are from different animals. Requirement 4: any ingredient meeting the requirements of items 1 to 3, which is characterized by that the antigen includes a pathogen, a toxin related pathogen, an attachment related pathogen, an undesirable strain or combination thereof. Claim 6: ingredients determined in accordance with claim 4, characterized by pathogens selected from a group consisting of Campylobacter jejuni, Salmonella, Salmonella enterica serovar Typhi, Shigella dystenterie,Plesiomonas shigelloides, Escherichia coli, enteropathogenic E. coli, enterotoxigenic E. coli, enteroaggregative E. coli, enteroinvasive E. coli, hemorrhagic E. coli, Clostridium difficulty, Yersinia enterocolitica, Vibrio cholerae O1, Vibrio O139, Non-O1 Vibrios, Vibrio, Vibrio, Vibrio, Vibrio parahaemolyticus, Aeromonas hydrophila, Clostridium perfringens, Helicobacter enterohepatic, Helicobacter pylori,
